Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $33.3 million.

  • Innate Pharma's Total Current Liabilities fell 1908.0% to $33.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $33.3 million, marking a year-over-year decrease of 1908.0%. This contributed to the annual value of $35.2 million for FY2024, which is 1735.58% down from last year.
  • Per Innate Pharma's latest filing, its Total Current Liabilities stood at $33.3 million for Q2 2025, which was down 1908.0% from $35.2 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Total Current Liabilities ranged from a high of $91.4 million in Q4 2021 and a low of $33.3 million during Q2 2025
  • In the last 5 years, Innate Pharma's Total Current Liabilities had a median value of $42.2 million in 2022 and averaged $50.8 million.
  • Examining YoY changes over the last 5 years, Innate Pharma's Total Current Liabilities showed a top increase of 6850.28% in 2021 and a maximum decrease of 9993.77% in 2021.
  • Quarter analysis of 5 years shows Innate Pharma's Total Current Liabilities stood at $91.4 million in 2021, then tumbled by 53.85% to $42.2 million in 2022, then grew by 1.12% to $42.6 million in 2023, then decreased by 17.36% to $35.2 million in 2024, then fell by 5.49% to $33.3 million in 2025.
  • Its Total Current Liabilities was $33.3 million in Q2 2025, compared to $35.2 million in Q4 2024 and $41.2 million in Q2 2024.